Varlitinib in Combination With mFOLFOX6 for Advanced or Metastatic Gastric Cancer (First Line)

PHASE2/PHASE3CompletedINTERVENTIONAL
Enrollment

52

Participants

Timeline

Start Date

August 31, 2017

Primary Completion Date

December 20, 2018

Study Completion Date

February 22, 2019

Conditions
Gastric Cancer
Interventions
DRUG

Varlitinib

300mg, oral tablets, twice daily for 2 weeks. Number of cycles: until disease progression, unacceptable toxicity, withdrawal of consent, or death.

DRUG

mFOLFOX6

concurrent oxaliplatin 85 mg/m2 and leucovorin 400 mg/m2 IV in 500 ml 5% dextrose water (D5W) over 120 minutes on Day 1; then 5 Fluorouracil bolus 400 mg/m2 IV on Day 1 followed by continuous infusion 2400 mg/ m2 over 46 hours starting on Day 1) every 2 weeks. Number of cycles: until disease progression, unacceptable toxicity, withdrawal of consent, or death.

DRUG

Placebo

oral tablets, twice daily for 2 weeks. Number of cycles: until disease progression, unacceptable toxicity, withdrawal of consent, or death.

DRUG

mFOLFOX6

concurrent oxaliplatin 85 mg/m2 and leucovorin 400 mg/m2 IV in 500 ml 5% dextrose water (D5W) over 120 minutes on Day 1; then 5 Fluorouracil bolus 400 mg/m2 IV on Day 1 followed by continuous infusion 2400 mg/ m2 over 46 hours starting on Day 1) every 2 weeks. Number of cycles: until disease progression, unacceptable toxicity, withdrawal of consent, or death.

Trial Locations (16)

Unknown

2 Sites, Tallinn

1 Site, Hong Kong

2 Sites, Kaunas

1 Site, Vilnius

2 Sites, Kuala Lumpur

1 Site, Singapore

2 Sites, Daegu

1 Site, Incheon

1 Site, Jeongnam

11 Sites, Seoul

2 Sites, Suwon

1 Site, Kaohsiung City

1 Site, Taichung

1 Site, Taipei

1 Site, Khon Kaen

1 Site, Pathum Thani

Sponsors
All Listed Sponsors
lead

ASLAN Pharmaceuticals

OTHER

NCT03130790 - Varlitinib in Combination With mFOLFOX6 for Advanced or Metastatic Gastric Cancer (First Line) | Biotech Hunter | Biotech Hunter